Clinical Edge Journal Scan

Microwave ablation: An alternative to resection in HCC with BCLC stage 0


 

Key clinical point: Among patients with hepatocellular carcinoma (HCC), an “ideal candidate for ablation” per the Barcelona Clinic Liver Cancer (BCLC) staging system may not be ideal for microwave ablation (MWA); however, patients with BCLC-0 disease may comprise the optimal population for MWA.

Major finding: Liver resection (LRE) vs MWA led to a significantly longer recurrence-free survival in the overall population ( P = .025) and patients with BCLC-A disease ( P = .003) but not in those with BCLC-0 disease ( P = .270), in addition to similar overall survival ( P = .976) and post-procedure-related complication rates ( P = 1.00) in BCLC-0 patients.

Study details: This retrospective study included patients with HCC who met the criteria of “ideal candidates for ablation” per the BCLC staging system and propensity score-matched those receiving MWA and LRE (overall population 140 pairs; BCLC-0 disease 35 pairs; BCLC-A disease 99 pairs).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Tong Y, Cai R et al. Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: A propensity score matching and inverse probability of treatment weighting analysis. Aliment Pharmacol Ther. 2022;56(11-12):1602-1614 (Oct 26). Doi: 10.1111/apt.17263

Recommended Reading

Alpha-fetoprotein: A real-time monitor in HCC treatment with atezolizumab and bevacizumab
Federal Practitioner
Commentary: Multifocal Hepatocellular Carcinoma, November 2022
Federal Practitioner
Advanced HCC: Antidrug antibody levels tied to outcomes in patients on atezolizumab/bevacizumab
Federal Practitioner
Bevacizumab use is questionable in liver cirrhosis with locally advanced HCC
Federal Practitioner
Immune checkpoint inhibitor rechallenge is effective and safe in HCC
Federal Practitioner
HCC: Atezolizumab+bevacizumab treatment outcome unaffected by the underlying liver etiology
Federal Practitioner
HAIC+lenvatinib+sequential ablation: An effective and safe treatment option for advanced HCC
Federal Practitioner
Alpha-fetoprotein and carbohydrate antigen 19-9: Prognostic markers in HCC after hepatectomy
Federal Practitioner
Atezolizumab+bevacizumab: A better first-line treatment option for unresectable HCC than lenvatinib
Federal Practitioner
Sequence of radiotherapy and TACE affects the prognosis of HCC with portal vein tumor thrombus
Federal Practitioner